MAP2K7 and uveal melanoma: Despite the reliance of uveal melanomas on the MAPK cascade, the inhibition of this pathway with clinically achievable doses of MEK inhibitors, alone or in combination with chemotherapy, fail to achieve a significant improvement in patient overall survival [14,15,17,59].